Opinions
Darren Sissons
Teva Pharmaceutical
TEVA-N
DON'T BUY
Jul 31, 2018
$23.940
Stock price when the opinion was issued
biotechnology
pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
DON'T BUY
They went from an in incredibly well managed drug company and then management decided to develop their own drugs and make mistakes. It is difficult to unwind these problems. Turning around a company like this will be difficult because of the debt. This is a highly speculative stock.
biotechnology
pharmaceutical
HOLD
Generic brand companies like Teva have struggled in the last 5 years has they competed with each others. Pfizer is in the process of buying one of their competitors and the Pfizer stock dropped 5$ on the announcement. Doesn't own Teva, purchased United Heatlth recently. You can hold but it's not a name he would hold due to the risk and they have no value added.
biotechnology
pharmaceutical
DON'T BUY
This company lost its identity as it evolved. Was it primarily a drug company or a marketer of generics? Its price dropped substantially after its main drug came off patent. Since then, the CEO left and the Board has reorganized. However, Teva still has a lot of debt. The debt load was moderate, but earnings have fallen so much that the debt has become relatively much more important, making this a risky investment. 16. 3M (MMM-N)(Doesn’t own)(Buy on weakness). This company did very well when value stocks were in favor, and has traded down. It is modestly priced compared to its historical levels, not cheap. This would be a good company to buy at a discount and hold for a long time.